3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
X-Rays
7
Phantoms, Imaging
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Nuclear Medicine Department, Hospital
5
Biopsy
4
Stem Cell Transplantation
3
Radiotherapy
3
Filgrastim
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
liposomal amphotericin B
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Voriconazole
2
Vincristine
2
Vemurafenib
2
Therapeutics
2
Polymerase Chain Reaction
2
Methylprednisolone
2
Melphalan
2
LY3023414
2
Itraconazole
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
Genistein
×
Lymphoid
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts